What Can You Expect in 2026?
Join a global community of DDR experts in Boston to explore the next frontier of targeted oncology. From validating novel DDR targets and refining biomarker-driven patient selection to integrating DDR inhibitors with ADCs, radiotherapy, and chemotherapy, this summit delivers actionable insights across discovery, translational science, and clinical development.
Expect high-impact case studies, strategic panels, and interactive roundtables designed to help you overcome resistance, improve safety, and fast-track your DDR pipeline. Whether you're a biotech innovator, academic researcher, or pharma leader, this is your must-attend meeting to drive progress in DDR therapeutics.

Unmissable Event Highlights:
Biomarker Breakthroughs
Discover the latest predictive and functional biomarkers from Merck, Step Pharma, and the University of Pennsylvania to guide smarter patient selection and dosing.
Smarter Combinations
Learn from Artios Pharma, VSPharmTech, and the University of Glasgow on combining DDR inhibitors with radiotherapy, ADCs, and chemotherapy to overcome resistance.
Expanding DDR Targets
Explore new data on ATR, CHK1/2, DNA-PK, WEE1, Polθ, and DHX9 from Oxford, Accent Therapeutics, Beat Therapeutics, and MD Anderson.
What’s New for 2026
Biotech Innovation & Academic to Industry Collaboration
Hear from Rakovina Therapeutics, Modifi Bio & Breakpoint Therapeutics on translating DDR discoveries into biotech ventures.
Focus on Translational Bottlenecks
Explore clinical setbacks and the reasons promising DDR targets fail with Merck, Roche, Mayo Clinic, EMD Serono and the Dana-Farber Cancer Institute.
Novel Modalities
Sessions on dual-payload ADCs, DDR-targeting antibodies, and synthetic lethality beyond PARP.
Attending Companies Include








